Caribou Biosciences initiated a strategic review after its stock extended losses, and the company said it would halt trials of its two clinical-phase allogeneic CAR-T programs while executing additional cost-reduction measures. The move reflects pressure from what management described as an unfavorable financing environment for the segment. The company’s earlier pipeline includes its off-the-shelf CAR-T approach in development following its CRISPR heritage, but the update marks a near-term retreat from clinical spend. For investors and peer companies, the announcement is a reminder that even late-stage science can struggle without capital access. Caribou’s decision also raises the bar for what new de-risked milestones may be needed to re-attract funding to allogeneic cell therapy platforms, particularly where manufacturing complexity and trial duration elongate cash burn.